Core Viewpoint - Artivion, Inc. will release its fourth quarter and full year 2024 financial results on February 24, 2025, after market close, followed by a teleconference to discuss the results [1]. Financial Results Announcement - The financial results will be announced on February 24, 2025, after market close [1]. - A teleconference call and live webcast will take place at 4:30 p.m. ET on the same day [1]. Teleconference Details - To participate in the live teleconference, interested parties should dial 201-689-8261 a few minutes before the start time [2]. - A replay of the teleconference will be available approximately one hour after the event, accessible via toll-free number 877-660-6853 or 201-612-7415, using conference number 13749878 [2]. Webcast and Earnings Release - The live webcast and replay can be accessed on the Investors section of Artivion's website [3]. - A copy of the earnings press release, containing financial and statistical information, will also be available on the Investors section of the website [3]. Company Overview - Artivion, Inc. is headquartered in suburban Atlanta, Georgia, and focuses on developing solutions for cardiac and vascular surgeons dealing with aortic diseases [4]. - The company offers four major product groups: aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues [4]. - Artivion markets its products in over 100 countries worldwide [4].

Core Insights - Artivion, Inc. announced positive one-year outcomes from the AMDS PERSEVERE clinical trial for treating acute DeBakey Type I aortic dissections complicated by malperfusion [1][3][5] Clinical Trial Data - The PERSEVERE trial involved 93 participants and demonstrated a sustained benefit of the AMDS device, with 80% of patients surviving through one year [3][6] - Key findings include a 20.4% all-cause mortality rate at one year, compared to 42.7% in historical controls, and a significant reduction in major adverse events (MAEs) [4][6] - The trial reported zero occurrences of distal anastomotic new entry (DANE) tears, which are common complications in similar procedures [4][7] Device Overview - The AMDS is the first aortic arch remodeling device designed for acute DeBakey Type I aortic dissections, allowing for rapid deployment during standard surgical procedures [7] - The device aims to improve patient outcomes by addressing complications associated with traditional hemiarch repairs, such as downstream true lumen expansion and false lumen treatment [8] Market Opportunity - Approximately 48,000 patients experience acute DeBakey Type I aortic dissections annually, representing a market opportunity of $150 million in the U.S. and $540 million globally [8] - The AMDS device is currently available in the U.S. under a Humanitarian Device Exemption (HDE) and is expected to receive premarket approval (PMA) by late 2025 [5][9]

Core Insights - Three stocks with strong momentum and buy rank are highlighted for investors: NextNav Inc., Vertex, Inc., and Artivion, Inc. [1][2][3] Company Summaries - **NextNav Inc. (NN)**: - Zacks Rank 1 - Current year earnings estimate increased by 7.5% over the last 60 days - Shares gained 72.1% over the last three months, outperforming the S&P 500's 3.9% increase - Momentum Score of A [1] - **Vertex, Inc. (VERX)**: - Zacks Rank 1 - Current year earnings estimate increased by 8.6% over the last 60 days - Shares gained 26.0% over the last three months, also outperforming the S&P 500's 3.9% increase - Momentum Score of A [2] - **Artivion, Inc. (AORT)**: - Zacks Rank 1 - Current year earnings estimate increased by 68.2% over the last 60 days - Shares gained 8.3% over the last three months, again outperforming the S&P 500's 3.9% increase - Momentum Score of A [3]

Group 1 - Artivion, Inc. (AORT) has seen a 68.2% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [1] - Vertex, Inc. (VERX) has experienced an 8.6% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [1] - NextNav Inc. (NN) has recorded a 7.5% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [2] - Immunocore Holdings plc (IMCR) has seen a 48.6% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [2] - EverQuote, Inc. (EVER) has experienced a 19.7% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [3]

Financial Performance - The company reported Q3 2024 revenue of $95.8 million, reflecting a 10% year-over-year growth in constant currency, and adjusted EBITDA increased by 28% year-over-year [9][33] - Adjusted EBITDA margin improved to 18.5%, a 270 basis point increase from the previous year, driven by a reduction in general, administrative, and marketing expenses as a percentage of sales [33] Product Line Performance - On-X revenues grew by 15% year-over-year in constant currency, attributed to market share gains and clinical benefits [10][34] - BioGlue experienced a 14% increase in revenue on a constant currency basis, marking the second consecutive quarter of double-digit growth [11][34] - Stent graft revenues rose by 13% year-over-year in constant currency, supported by a differentiated product portfolio [12][34] - Tissue processing revenues grew by 2% year-over-year, impacted by lower donor allograft volumes [14][34] Geographic Performance - Revenue growth in Latin America was 32% and 23% in Asia Pacific, driven by regulatory approvals and commercial expansion [18][36] - EMEA revenues increased by 15%, while North America saw a modest growth of 2% [36] Company Strategy and Industry Competition - The company is focused on expanding its product portfolio and regulatory approvals, with significant growth opportunities in the U.S. and Japan markets for stent grafts [13][19] - The company anticipates FDA approval for AMDS in Q4 2025, which could open a $150 million market with no competitive alternatives [19][49] - The recent regulatory approval for BioGlue in China is expected to create a significant market opportunity, with commercialization anticipated in the second half of 2025 [20][21] Management Commentary on Operating Environment and Future Outlook - Management expressed confidence in sustaining double-digit revenue growth and driving EBITDA growth at twice the rate of revenue [31][48] - The company expects to maintain gross margins similar to 2023 levels and anticipates continued leverage from its global sales force [44][88] - For 2025, the company expects similar growth dynamics as in 2024, with no significant revenue from AMDS anticipated until 2026 [46][73] Other Important Information - Free cash flow for Q3 2024 was $7.8 million, with expectations for positive free cash flow for the full year [39] - The company’s net leverage decreased to 3.9x, down from 5.3x in the prior year, with expectations for further reduction [41] Q&A Session Summary Question: Insights on aortic stent graft business performance - Management noted strong double-digit growth across multiple products in the aortic stent graft segment, with significant market presence in Europe, Asia, and Latin America [53][54] Question: Market share gains for On-X - The company holds approximately 30% global market share and 55% in the U.S., with expectations for continued growth driven by clinical data showing reduced bleeding [55][57] Question: Long-term growth for SynerGraft - Management highlighted the challenge of donor constraints impacting growth, but ongoing improvements in donor yields are expected to support mid-single-digit growth in the long term [60][61] Question: Launch strategy for AMDS - A soft launch is anticipated in Q4 2025 following FDA approval, with a gradual ramp-up as surgeons are trained and hospitals are onboarded [70][73] Question: BioGlue market opportunity in China - The estimated market opportunity remains around $20 million, with a gradual rollout expected over several years post-approval [80][82] Question: Impact of PerClot manufacturing agreement - The agreement is expected to create a slight headwind of less than 1 percentage point in revenue, with minimal impact on EBITDA [84]

Revenue Performance - Artivion reported quarterly revenues of $95.8 million for the three months ended September 30, 2024, representing a 9% increase from $87.9 million in the same period of 2023[107]. - Revenues from aortic stent grafts increased by 12% to $28.6 million for the three months ended September 30, 2024, compared to $25.5 million in 2023[113]. - On-X product revenues rose by 15% to $21.5 million for the three months ended September 30, 2024, up from $18.7 million in the prior year[113]. - Surgical sealants revenues increased by 14% to $18.4 million for the three months ended September 30, 2024, compared to $16.2 million in 2023[113]. - Constant currency revenues increased by 10% for the three months ended September 30, 2024, compared to the same period in 2023[120]. - Total revenues for the nine months ended September 30, 2024, were $291.2 million, a 12% increase from $260.3 million in the same period of 2023[114]. - Preservation services revenues increased by 11% to $75.7 million for the nine months ended September 30, 2024, compared to $68.3 million in 2023[114]. - Aortic stent grafts accounted for 32% of total revenues for the nine months ended September 30, 2024[114]. Cost and Expenses - Cost of products increased 13% for the three months ended September 30, 2024, compared to the same period in 2023, driven by an increase in the volume of all products shipped[144]. - General, administrative, and marketing expenses decreased 2% for the three months ended September 30, 2024, compared to the same period in 2023, primarily due to a decrease in business development expenses[151]. - Research and development expenses increased by 3% to $6.605 million for the three months ended September 30, 2024, compared to $6.421 million for the same period in 2023, while remaining flat at $21.048 million for the nine months ended September 30, 2024, compared to $21.062 million in 2023[153]. Profitability and Loss - The company incurred a net loss of $2.288 million for the three months ended September 30, 2024, compared to a net loss of $9.801 million for the same period in 2023[158]. - The effective income tax rate was 81% for the three months ended September 30, 2024, compared to 4% for the same period in 2023, primarily due to changes in anticipated pre-tax operating results[159]. Cash Flow and Liquidity - As of September 30, 2024, net cash provided by operating activities was $12.1 million, compared to $8.0 million for the same period in 2023, representing a 51.25% increase[181]. - Net cash used in investing activities was $16.8 million for the nine months ended September 30, 2024, compared to net cash provided of $2.2 million for the same period in 2023[184]. - Net cash provided by financing activities was $2.0 million for the nine months ended September 30, 2024, down from $2.5 million in 2023[185]. - The company believes its cash from operations and existing cash and cash equivalents will meet its current operational liquidity needs for at least the next twelve months[170]. Debt and Financing - Interest expense rose to $8.4 million and $24.5 million for the three and nine months ended September 30, 2024, respectively, compared to $6.6 million and $19.1 million for the same periods in 2023, primarily due to increased interest rates from debt refinancing[155]. - A loss on extinguishment of debt of $3.7 million was recorded during the nine months ended September 30, 2024, related to the extinguishment of a previously existing term loan[156]. - The company entered into a credit and guaranty agreement for $350.0 million on January 18, 2024, which includes a $190.0 million secured term loan facility and a $60.0 million secured revolving credit facility[171]. - The company has $100.3 million in scheduled principal payments and $4.3 million in anticipated interest payments related to Convertible Senior Notes[186]. - Loans under the Term Loan Facilities bear interest at a floating annual rate with a margin of 5.50%, which may step down based on the total net leverage ratio[175]. Foreign Exchange Impact - Artivion's sales are impacted by foreign exchange fluctuations, with the US Dollar strengthening against major currencies affecting revenue translation for the three months ended September 30, 2024[122]. - A 10% adverse change in exchange rates could impact the company's financial position or cash flows by approximately $9.0 million[195]. Other Financial Metrics - Gross margin increased 8% for the three months ended September 30, 2024, compared to the same period in 2023, attributed to an increase in volume and favorable pricing of surgical sealants and On-X products[148]. - Domestic revenues from On-X products accounted for 59% of total On-X revenues for the three months ended September 30, 2024, down from 61% in the same period in 2023[131]. - Other revenues decreased 17% for the three months ended September 30, 2024, primarily due to a decrease in PerClot product revenues[138]. - The fair value of the Convertible Senior Notes as of September 30, 2024, was approximately $125.4 million with an effective interest rate of 5.05%[176]. - Approximately 38% of cash and cash equivalents were held in foreign jurisdictions as of September 30, 2024[179].

Artivion (AORT) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to earnings of $0.02 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 300%. A quarter ago, it was expected that this biological medical device maker would post earnings of $0.03 per share when it actually produced earnings of $0.07, delivering a surprise of 133.33%.Over the last four quarte ...

Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: Artivion Gilmartin Group LLC Lance A. Berry Brian Johnston / Laine Morgan Executive Vice President & Phone: 332-895-3222 Chief Financial Officer investors@artivion.com Phone: 770-419-3355 Artivion Reports Third Quarter 2024 Financial Results Third Quarter Highlights: • Achieved revenue of $95.8 million in the third quarter of 2024 versus $87.9 million in the third quarter of 2023, an increase of 9% on a GAAP basis and 10% on a non-GAAP constant currency basis • N ...

Third Quarter Highlights: Achieved revenue of $95.8 million in the third quarter of 2024 versus $87.9 million in the third quarter of 2023, an increase of 9% on a GAAP basis and 10% on a non-GAAP constant currency basis Net loss was ($2.3) million or ($0.05) per fully diluted share and non-GAAP net income was $5.0 million or $0.12 per fully diluted share in the third quarter of 2024 Adjusted EBITDA increased 28% to $17.7 million in the third quarter of 2024 compared to $13.9 million in the third quarter of ...

ATLANTA, Nov. 5, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming investor conferences.Artivion's management team will present at the upcoming Stifel 2024 Healthcare Conference on Tuesday, November 19, 2024, at the Lotte New York Palace. The Company's presentation is scheduled to begin at 1:15p.m. ET. A live webcast can be accessed through Artivion's website, www.artivion.com, ...